This treatment is called Pembrolizumab, a monoclonal antibody that helps the immune system detect and eliminate malignant cells.

Triple-negative breast cancer is one of the most aggressive and rapidly spreading types of cancer, affecting between 10 and 15 percent of patients with this disease.

Ximena Aguilera, head of the Ministry of Health, explained that this drug completely changes the chances of survival for affected women.

The Ministry of Health estimates that 650 women will benefit annually from this treatment through its inclusion in the Zero Co-Payment system, which has benefited 1.9 million people in its three years of implementation.

This way, progress is being made in reducing the access gap between the public and private systems, Aguilera said.

Breast cancer is the most common cancer among women in Chile, with 5,640 diagnoses per year, and it is also the leading cause of cancer-related death in this group, with six deaths per day.

jdt/mem/car